GFG
CORT icon

Goldstone Financial Group’s Corcept Therapeutics CORT Stock Holding History

Goldstone Financial Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
14,571
+2,443
+20% +$148K 0.12% 106
2026
Q1 		$489K Buy
12,128
+1,034
+9% +$38.7K 0.05% 169
2025
Q4 		$386K Buy
11,094
+791
+8% +$62.1K 0.04% 177
2025
Q3 		$856K Buy
10,303
+3,919
+61% +$284K 0.1% 122
2025
Q2 		$461K Buy
6,384
+1,598
+33% +$116K 0.06% 160
2025
Q1 		$547K Buy
+4,786
New +$291K 0.08% 126

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldstone Financial Group's CORT Position: Q2 2026 in Review

Goldstone Financial Group increased its Corcept Therapeutics (CORT) stake by 20% in Q2 2026, buying an estimated $148K and bringing the position to 14,571 shares worth $1.27M. The position accounts for 0.12% of the portfolio, ranked #106.

Goldstone Financial Group first reported a position in CORT in Q1 2025 and has held it in 6 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Goldstone Financial Group held 14,571 shares of Corcept Therapeutics worth $1.27M as of Q2 2026.
  • Goldstone Financial Group bought 2,443 Corcept Therapeutics shares in Q2 2026, an estimated $148K.
  • Corcept Therapeutics made up 0.12% of Goldstone Financial Group's portfolio in Q2 2026, its #106 holding.
  • Goldstone Financial Group first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Goldstone Financial Group's 13F filing for Q2 2026, filed 11 Aug 2026.